Overview

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Status:
RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer
Phase:
PHASE3
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Treatments:
Ado-Trastuzumab Emtansine